Donate For Public and Patients Store Search

S013 - Contact Dermatitis

Friday, March 1; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Identify of new and upcoming allergens and common allergens in soaps, sunscreens and other personal care products.
  • Assess of the patient with occupational contact dermatitis.
  • Discuss and manage of challenges within patch testing including immunosuppressants, metal devices and patients with atopic dermatitis.

Description

This session is intended to provide information on upcoming and new allergens as well as a discussion of allergens seen in common personal care allergens products such as shampoos, soaps and sunscreens. It will also discuss the approach to the occupational contact dermatitis patient and the patient with atopic dermatitis who is in need of patch testing. Challenges within the field of contact dermatitis including testing while on immunosuppressants and metal devices and patch testing will be addressed. This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org.

Disclosures

  • Anderson, Bryan Erik, MD: no financial relationships exist with commercial interests.
  • Dunnick, Cory A., MD: AbbVie – I(Grants/Research Funding); Celgene – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding);
  • Hurley, M. Yadira, MD: Actelion – C(H), I(Grants/Research Funding), SP(H); Centocor Ortho Biotech Inc. – I(Grants/Research Funding); Elorac, Inc. – I(Grants/Research Funding); Genentech, Inc. – I(Grants/Research Funding); Helsinn Healthcare – A(H), SP(H); InflaRx GmbH – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); PellePharm, Inc. – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Regeneron – I(Grants/Research Funding);
  • Ko, Christine, MD: Elsevier Inc. – O(IP); Wiley-Blackwell – O(IP);
  • Lampel, Heather P., MD, MPH: Merz Aesthetics – E(S);
  • Mowad, Christen M., MD: AbbVie – E(S); Elsevier Inc. – B(H); UpToDate, Inc – O(IP);
  • Silverberg, Jonathan I., MD, PhD, MPH: AbbVie – C(H), I(NC); AnaptysBio – C(H); Asana Biosciences, LLC – C(H); Dermira – A(H); Eli Lilly and Company – C(H), I(NC); Galderma Research & Development, LLC – C(H); GlaxoSmithKline – C(H), I(NC); Glenmark Generics Inc. – C(H); Kiniksa Pharmaceuticals, Ltd. – C(H), I(NC); Leo Pharma Inc – A(H); Leo Pharma Inc. – I(H); Medimmune – C(H); Menlo Therapeutics – A(H), I(NC); Pfizer Inc. – A(H), C(H); Regeneron – C(H), I(NC), SP(H); Sanofi – C(Grants/Research Funding);
  • Wu, Peggy, MD: American Academy of Dermatology – O(NC); Journal of the American Academy of Dermatology – O(NC); National Eczema Association – Data Safety Monitoring Board(H); UpToDate, Inc – Speaker/Faculty Education(H);
Schedule
Friday, March 1
1:00 PM
Dr. Lampel / Occupational Contact Dermatitis Update
1:30 PM
Dr. Anderson / New and Upcoming Allergens
2:00 PM
Dr. Silverberg / Atopic Dermatitis and Patch Testing
2:30 PM
Dr. Wu / Challenges in Patch Testing
3:00 PM
Dr. Dunnick / Shampoos, Soaps and Sunscreens
3:30 PM
Dr. Mowad / Metal Devices and Patch Testing
Event Details
  • Date
    Friday, March 1
  • Time
    1:00 PM - 4:00 PM
  • Location
    Salon G
  • CME Credits
    3.00
  • Type
    MOC
Directors/Co-Directors
  • Christen M. Mowad, MD, FAAD
Speakers
  • Bryan Erik Anderson, MD, FAAD
  • Christine Ko, MD, FAAD
  • Cory A. Dunnick, MD, FAAD - Handout
  • Heather P. Lampel, MD, MPH, FAAD - Handout
  • Jonathan I. Silverberg, MD, PhD, MPH, FAAD
  • M. Yadira Hurley, MD, FAAD
  • Peggy Wu, MD, FAAD - Handout